

112
comprising administering the vaccine of claim 48 to said mammal at a dosage sufficient to induce protective immunity against subsequent infection with at least one strain of said lentivirus.

The amended claims in mark-up form are as follows:

66. (AMENDED) The method of claim [64 or] 65, further comprising purifying the antibody from the animal.

70. (AMENDED) A method of inducing an immune response in a mammal, comprising administering the vaccine of claim 48[, 49 or] 50 to said mammal at a dosage sufficient to induce protective immunity against subsequent infection with at least one strain of said lentivirus.

Please add new claims 72 and 73 as follows:

113
72. (NEW) A method of inducing an immune response in a mammal, comprising administering the vaccine of claim 50 to said mammal at a dosage sufficient to induce protective immunity against subsequent infection with at least one strain of said lentivirus.

73. (NEW) The method of claim 72, wherein said mammal is a cat, said lentivirus is a strain of FIV and said vaccine is administered at a dosage sufficient to induce protective immunity against subsequent infection by at least one strain of FIV.

REMARKS


Claims 1-71 were pending in the prior copending application. By this amendment, claims 1-35, 49, 62-64, and 67-69 have been cancelled without prejudice to applicants' rights therein. Claims 66 and 70 have been amended to delete references to cancelled claims and to remove multiple dependency. New claims 72 and 73 have been added herein. Accordingly, claims are pending and under examination.

New claim 72 has support throughout the subject application, inter alia, in original claim 70. New claim 73 has support throughout the subject application, inter alia, in original claim 70 and 71. No issue of new matter is raised by the present amendment. Therefore, entry of the amendments set forth herein is respectfully requested.

No fee is believed to be necessary in connection with this Preliminary Amendment. Authorization, however, is hereby provided to charge any fee deemed required, or to credit any overpayment, to Deposit Account No. 16-1445.

Applicants believe the present claims are allowable, and respectfully request expeditious examination of the pending claims on the merits.

Respectfully submitted,



Date: December 15, 2000

A. David Joran
Attorney for Applicants
Reg. No. 37,858

Pfizer Inc
Patent Department, 20th Floor
235 East 42nd Street
New York, NY 10017-5755
(212) 212-733-3381

0073047-212733-3381